Status:
COMPLETED
Behavioral Economic Strategies to Improve PRO Adherence
Lead Sponsor:
Abramson Cancer Center at Penn Medicine
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The main purpose of this research study is to evaluate the implementation and effectiveness of patient- and nurse-directed strategies across in-clinic and remote patient reported outcome (PRO) monitor...
Detailed Description
Routine PRO monitoring is an evidence-based practice that improves patient outcomes. Patients with cancer commonly experience symptoms which go unrecognized by clinical teams up to half of the time. P...
Eligibility Criteria
Inclusion
- Patients must initiate a new line of systemic cancer therapy (i.e., intravenous chemotherapy or immunotherapy) at a participating Implementation Lab site
Exclusion
- \- Patient opts out of pragmatic research
Key Trial Info
Start Date :
December 4 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 4 2024
Estimated Enrollment :
476 Patients enrolled
Trial Details
Trial ID
NCT06013176
Start Date
December 4 2023
End Date
September 4 2024
Last Update
December 29 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Penn Medicine Princeton Health
Plainsboro, New Jersey, United States, 08536
2
Abramson Cancer Center
Philadelphia, Pennsylvania, United States, 19104